Should the FDA ease restrictions on compounded peptides? The debate is heating up. ⚠️ An FDA advisory panel is voting this week on whether to allow seven peptides—including TB-500 and BPC-157—to be sold as compounded medications. Proponents describe them as a “fountain of youth” for healing and wellness, but doctors warn the safety and effectiveness haven’t been adequately studied. The peptides are being reviewed as potential treatments for conditions like ulcerative colitis, wound healing, obesity, and migraine. While some experts say peptides show therapeutic promise, others stress there’s limited research on long-term effects and potential risks. FDA scientists have raised concerns about the lack of scientific evidence and safety data. ⚠️Medical experts emphasize these substances should be held to the same standards as any other drug. 🔗 Tap the link in bio for expert insight on what’s at stake in this FDA decision. Post Fact Checked By: Cynthia Taylor Chavoustie, MPAS, PA-C ...